

Resource Summary Report

Generated by T1D on Aug 2, 2026

NanoString: GeoMx Digital Spatial Profiler

RRID:SCR_021660

Type: Tool

Proper Citation

NanoString: GeoMx Digital Spatial Profiler (RRID:SCR_021660)

Resource Information

URL: <https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp-overview/>

Proper Citation: NanoString: GeoMx Digital Spatial Profiler (RRID:SCR_021660)

Description: Integrated commercial system comprising hardware, software and nCounter chemistry that enables simultaneous, highly multiplex spatial profiling of proteins or RNA in FFPE tissues. DSP platform quantifies abundance of protein or RNA by counting unique indexing oligonucleotides assigned to each target of interest. Used to rapidly and quantitatively assess biological implications of heterogeneity within tissue samples.

Abbreviations: GeoMx DSP

Synonyms: GeoMx Digital Spatial Profiler

Resource Type: instrument resource

Defining Citation: [PMID:32393914](#)

Keywords: Spatial profiling, proteins spatial profiling, RNA spatial profiling, NanoString, counting unique indexing oligonucleotides, tissue heterogeneity, Digital Spatial Profiler, instrument, equipment, USEdit

Availability: Restricted

Resource Name: NanoString: GeoMx Digital Spatial Profiler

Resource ID: SCR_021660

Record Creation Time: 20220129T080356+0000

Record Last Update: 20260801T190722+0000

Ratings and Alerts

No rating or validation information has been found for NanoString: GeoMx Digital Spatial Profiler.

No alerts have been found for NanoString: GeoMx Digital Spatial Profiler.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. Cancer research communications, 6(1), 17.

Knisely A, et al. (2025) Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4122.

Burns GW, et al. (2025) Spatial transcriptomic analysis identifies epithelium-macrophage crosstalk in endometriotic lesions. iScience, 28(2), 111790.

Lim SH, et al. (2025) Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(8), 1476.

Kim S, et al. (2025) Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience, 28(2), 111736.

Gregory RC, et al. (2025) In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma. Cancer research communications, 5(7), 1243.

Li J, et al. (2025) Mutational Analysis of Early, Low-Grade Bowel Polyps Defines a Subgroup with Concurrent, High-Risk Oncogenic Drivers Independent of Polyp Size. Cancer research communications, 5(8), 1372.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. Cancer discovery, 15(6), 1203.

Rademacher K, et al. (2025) Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration. eLife, 13.

Gobbini E, et al. (2025) The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma. *Cancer immunology research*, 13(4), 517.

Lou E, et al. (2025) SARS-CoV-2 infection drives local inflammation of the intestinal epithelium in immunocompromised patients with cancer. *iScience*, 28(9), 113438.

Colevas AD, et al. (2025) First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 815.

Stein-O'Brien GL, et al. (2025) Transcriptional signatures of hippocampal tau pathology in primary age-related tauopathy and Alzheimer's disease. *Cell reports*, 44(3), 115422.

Rademacher K, et al. (2024) Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration. *bioRxiv : the preprint server for biology*.

Yamaguchi J, et al. (2024) PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis. *The Journal of clinical investigation*, 134(15).

El Shami M, et al. (2023) Human plasma-like medium facilitates metabolic tracing and enables upregulation of immune signaling pathways in glioblastoma explants. *bioRxiv : the preprint server for biology*.

Arbore G, et al. (2023) Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. *Cancer research*, 83(17), 2873.

Fisher NC, et al. (2022) Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(18), 4056.

Polverino F, et al. (2022) Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer. *Scientific reports*, 12(1), 22402.

Wang Y, et al. (2022) Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis. *Cancer research*, 82(24), 4528.